Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Samuel Isaly Reported Changes in His Third Quarter Holdings

Samuel Isaly reported his amended 13F portfolio on November 23rd. He made a lot of changes to his original third quarter 13F which was filed a few days ago. He disclosed that he sold his entire stakes in 12 stocks, including Alnylam Pharmaceuticals Inc. (ALNY), Ariad Pharmaceuticals Inc. (ARIC), China Nuokang Bio-Pharm Inc. (NKBP), Dendreon Corp (DNDN), Endocyte Inc. (ECYT), Impax Laboratories Inc. (IPXL), Ishares Tr (GRG), Pernix Therapeutics Hldgs In (PTX), Savient Pharmaceuticals Inc. (SVNT), St Jude Med Inc. (STJ), Teva Pharmaceutical Inds Ltd (TEVA), and Vertex Pharmaceuticals Inc. (VRTX).

Samuel Isaly also complemented 11 positions in his amended 13F, including Allos Therapeutics Inc. (ALTH), Covidien Plc (COV), Idenix Pharmaceuticals Inc. (IDIX), Insmed Inc. (INSM), Intermune Inc. (ITMN), Mylan Inc. (MYL), Orexigen Therapeutics Inc. (OREX), Questcor Pharmaceuticals Inc. (QCOR), Sanofi (SNY), Targacept Inc. (TRGT), and United Therapeutics Corp Del (UTHR).

Pfizer Inc. (NYSE:PFE)

According to the latest amended 13F filing, Samuel Isaly took 9.75 million shares in Allos Therapeutics Inc. (ALTH), 8.98 million shares in Antares Pharma Inc. (AIS), and 6.73 million shares in Pfizer Inc. (PFE). These are the top three positions in Samuel Isaly’s portfolio. Samuel Isaly did not make change to these positions after the second quarter.

Samuel Isaly’s Orbimed Advisors is the world’s largest healthcare-dedicated investment firm. The firm has with approximately $5 billion in assets under management. The firm was founded in 1989 with a vision to invest across the spectrum of healthcare companies. The firm manages a series of venture capital funds and public equity investment funds.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!